Essential Role for the p55 Tumor Necrosis Factor Receptor in Regulating Hematopoiesis at a Stem Cell Level

By Vivienne I. Rebel,* ‡ Sheila Hartnett,* ‡ Geoffrey R. Hill,* ‡ Suzan B. Lazo-Kallanian,§ James L.M. Ferrara,* ‡ and Colin A. Sieff ‡

From the *Department of Pediatric Oncology, the ‡Department of Hematology, and the §Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115

Summary

Hematopoietic stem cell (HSC) self-renewal is a complicated process, and its regulatory mechanisms are poorly understood. Previous studies have identified tumor necrosis factor (TNF)-α as a pleiotropic cytokine, which, among other actions, prevents various hematopoietic progenitor cells from proliferating and differentiating in vitro. However, its role in regulating long-term repopulating HSCs in vivo has not been investigated. In this study, mice deficient for the p55 or the p75 subunit of the TNF receptor were analyzed in a variety of hematopoietic progenitor and stem cell assays. In older p55−/− mice (>6 mo), we identified significant differences in their hematopoietic system compared with age-matched p75−/− or wild-type counterparts. Increased marrow cellularity and increased numbers of myeloid and erythroid colony-forming progenitor cells (CFCs), paralleled by elevated peripheral blood cell counts, were found in p55-deficient mice. In contrast to the increased myeloid compartment, pre-B CFCs were deficient in older p55−/− mice. In addition, a fourfold decrease in the number of HSCs could be demonstrated in a competitive repopulating assay. Secondary transplantations of marrow cells from primary recipients of p55−/− marrow revealed impaired self-renewal ability of p55-deficient HSCs. These data show that, in vivo, signaling through the p55 subunit of the TNF receptor is essential for regulating hematopoiesis at the stem cell level.

Key words: hematopoietic stem cell • cell differentiation • cytokine receptors

T

umor necrosis factor (TNF)-α, originally identified for its cytotoxic effect on certain murine tumors (1), is a pleiotropic cytokine that plays a pivotal regulatory role in immune and inflammatory responses (2). Its effects are mediated through two functionally distinct cell surface receptors, designated as the p55 and the p75 TNFR (3). The activities of TNF-α are predominantly mediated by the p55 receptor, and it has been postulated that the role of the p75 receptor is primarily to enhance signaling through the p55 receptor (4). However, p55 TNFR-independent signaling through the p75 receptor has been implicated in thymocyte proliferation, apoptosis of activated mature T cells, and various other host defense mechanisms (5–9). In hematopoiesis, TNF-α has been shown to both inhibit and stimulate proliferation, depending on the maturation stage of the cell and other cytokines involved (10–13). Besides its direct effect on hematopoietic cells (10, 13), TNF-α can exert its influence indirectly through the upregulation of other cytokine receptors (10, 14–17). Furthermore, TNF-α can stimulate other hematopoietic cells or cells of the microenvironment to produce cytokines involved in hematopoietic cell proliferation and/or differentiation (10, 17–24).

Hematopoietic stem cells (HSCs) are responsible for the steady state continuous generation of lineage-committed progenitor cells, which then give rise to the different types of mature blood cells. In response to various stimuli in situations that require rapid generation of mature blood cells, such as myeloablation, HSCs are able to increase the production of progenitor cells dramatically (25, 26). Despite the enormous dynamic proliferative nature of HSCs, the incidence of malignant transformation or bone marrow failure is very low, indicating that the proliferation of these cells is under tight control. One of the control mechanisms is to prevent HSCs from entering the cell cycle. It has been demonstrated that an autocrine production of
TNF-α has been shown to have a similar regulatory effect on HSCs in culture. Moreover, TNF-α cooperates with TNF-β in suppressing the proliferation of primitive Lin− Thy−1− progenitors of the mouse.

Although there is ample evidence to support the notion that TNF-α plays an inhibitory role in the regulation of proliferation of primitive progenitors, little is known about its activity on true long-term repopulating HSCs. Such knowledge may be critical for ex vivo stem cell manipulation protocols, e.g., gene therapy. The in vitro studies of the effects of TNF-α on HSCs have been limited by the difficulty in obtaining functionally uniform populations of these cells. However, the availability of mice lacking the p55 or the p75 TNFR makes it possible to circumvent this problem. We have now studied the role of TNFR signaling in HSCs by transplanting BM cells from wild-type (WT), p55−/−, or p75−/− donor mice into lethally irradiated recipients and directly assessing the ability of the graft to reconstitute all hematopoietic lineages long-term. Because the turnover time of the HSC pool is approximated at 30 d or more (33, 34), we hypothesized that lack of signaling through a TNFR would likely appear later in life. Therefore, we compared hematopoietic cell populations from old and young knockout mice with that of age-matched WT mice. Except for a higher number of myeloid CFU in the BM of p55−/− mice, we found no significant differences in any aspect of hematopoiesis between knockout and WT mice at a young age (<3 mo). In contrast, the BM of older p55−/− mice (>6 mo) showed significantly lower numbers of HSCs compared with WT mice, whereas progenitor cells and the more mature cell populations had increased in size. The only cell compartment that did not increase was the B cell lineage. Thus, these findings demonstrate an important role for signaling through the p55 TNFR in maintaining the HSC pool.

Materials and Methods

Mouse Strains. p55- and p75-deficient mice, originally supplied by Immunex Corp. to J. L. M. Ferrara, and C57BL/6 WT animals (The Jackson Laboratory) were bred and maintained at the Redstone Animal Facility of the Dana-Farber Cancer Institute. Congenic Ly5.1+ C57BL/6 mice were purchased from the National Institutes of Health. All animals were kept under microisolator conditions with food and water ad libitum.

Cell Preparations. To obtain peripheral blood (PB) samples, mice were first anesthetized by metaphane inhalation. For white blood cell (WBC) and RBC counts, the mice were terminally bled via a tail incision and the cell content of a tibia is counted with a hemocytometer. Assuming that the cell content of a tibia is ~0.6 that of a femur (35), the total cell number was divided by 3.2 to calculate the cell number per femur.

Materials and Methods

Mouse Strains. p55- and p75-deficient mice, originally supplied by Immunex Corp. to J. L. M. Ferrara, and C57BL/6 WT animals (The Jackson Laboratory) were bred and maintained at the Redstone Animal Facility of the Dana-Farber Cancer Institute. Congenic Ly5.1+ C57BL/6 mice were purchased from the National Institutes of Health. All animals were kept under microisolator conditions with food and water ad libitum.

Cell Preparations. To obtain peripheral blood (PB) samples, mice were first anesthetized by metaphane inhalation. For white blood cell (WBC) and RBC counts, the mice were terminally bled via a tail incision and the cell content of a tibia is counted with a hemocytometer. Assuming that the cell content of a tibia is ~0.6 that of a femur (35), the total cell number was divided by 3.2 to calculate the cell number per femur.

FACS® Analysis and Cell Sorting. To determine the presence of the different lineages in the BM, cells were incubated on ice for 35 min with the FITC-conjugated lineage (Lin) markers B220 (RA3-6B2), Mac-1 (M1/70), Gr-1 (RB6-8C5), Ly-1 (53-7.3), or PE-conjugated Ter119 (PharMingen). Cells were then washed twice with PBS, 2% FBS. The medium contained propidium iodide (PI, 2 μg/ml; Sigma Chemical Co.) to stain the dead cells. Cells were analyzed on a single laser FACSscan™ (Becton Dickinson).

For purification, cells were labeled with a cocktail of mAbs, including Sca-1, derivatized with cyanine 5 succinimidyl ester (a gift from Dr. P. Lansdorp, Terry Fox Laboratory, Vancouver, British Columbia, Canada), FITC-labeled Lin markers, and (PE)-conjugated c-Kit (2B8; PharMingen). Where indicated, CD34-FITC C (RAM34; PharMingen) was used to further subdivide the Sca-1+Lin+ c-Kit+ subpopulation into CD34− and CD34+ cells. A preenrichment step was included in the purification protocol when cells were sorted; total BM cells were depleted of cells that expressed mature Lin markers by magnetic separation according to the manufacturer’s directions (StemCell Technologies). Multicolor analysis to identify and sort Sca-1+Lin−/lo-c-Kit+ progenitor cells was performed on a Coulter Epics® Elite ESP.

To calculate the absolute number of each cell type per femur (i.e., the different mature cell lineages and Sca-1+Lin−/lo-c-Kit− cells), the total number of cells per femur was multiplied by the fraction of each cell population in total BM cells as obtained by FACS® analysis.

Cell Cycle Analysis. Unseparated BM cells or highly purified progenitor cells were fixed in ice-cold 80% ethanol and kept on ice overnight. The next day, cells were spun down and washed once in PBS with 0.1% Triton X-100. Cells were resuspended in 0.5 ml PBS containing 50 μg/ml PI, incubated at 37°C for 30 min, and then kept on ice until analysis, which was within 1–2 h of finishing the staining. The sample was analyzed on a Coulter Epics® XL analyzer.

In Vitro Assay for CFU in the Spleen and Competitive Repopulating Units. The BM content of CFU-S day 12 cells was determined as originally described (36). In brief, 7 × 10^4 unseparated BM cells were injected into C57BL/6 recipients that were irradiated with 950 cGy given in two equally split doses (5 h apart) from a ^37Cs source. The spleens were harvested 12 d later, and the macroscopic surface colonies were counted. The spleens of control animals that were irradiated but not transplanted with BM cells showed none or one to two pin-point size colonies. This size of colony was not included in the colony counts of the spleens from test animals. The number of CFU-S per femur was calculated by multiplying the number of nucleated cells per femur with the frequency of each progenitor, i.e., the number of respective colonies counted divided by the number of cells plated (5 × 10^6 cells for the pre-B cell assay and 1.5 × 10^4 cells for the erythroid/myeloid colony assay).

In Vivo Assay for CFU in the Spleen and Competitive Repopulating Units. The BM content of CFU-S day 12 cells was determined as originally described (36). In brief, 7 × 10^4 unseparated BM cells were injected into C57BL/6 recipients that were irradiated with 950 cGy given in two equally split doses (5 h apart) from a ^37Cs source. The spleens were harvested 12 d later, and the macroscopic surface colonies were counted. The spleens of control animals that were irradiated but not transplanted with BM cells showed none or one to two pin-point size colonies. This size of colony was not included in the colony counts of the spleens from test animals. The number of CFU-S per femur was calculated by multiplying the number of nucleated cells per femur with the frequency of CFU-S, i.e., number of colonies counted divided by 7 × 10^4.
A slightly modified competitive repopulating units (CRU) assay was used to determine the number of HSCs in BM (37, 38). In brief, varying doses of unseparated test cells (Ly5.2<sup>+</sup>) were injected together with 1 × 10<sup>5</sup> unseparated adult BM “helper” cells (Ly5.1<sup>+</sup>) into lethally irradiated (as for CFU-S) recipients (Ly5.1<sup>+</sup>). The allelic difference at the Ly5 locus between the recipient/helper cells and the test cell population was used to follow hematopoietic reconstitution from the test cells. 4, 8, and 16 wk after the transplantation, a small blood sample was taken from each mouse and analyzed for the presence of Ly5.2<sup>+</sup> cells. A mouse was considered to be reconstituted by CRU present in the test cell population (“positive”) when, 16 wk after the transplantation, >1% of the PB cells were Ly5.2<sup>+</sup> and included both myeloid and lymphoid cells, as determined by their respective distinct side scatter (SSC) properties. CRU frequencies for every type of BM tested were calculated by analysis of the proportion of negative mice using Poisson statistics (39). The number of CRU per femur was calculated by multiplying the number of nucleated cells per femur with the frequency of CRU.

Some transplanted mice were used as donors for secondary BM transplantations. Marrow cells from both femurs and tibiae were isolated, and a proportion of these cells together with Ly5.1<sup>+</sup> helper cells was injected into three to five irradiated Ly5.1<sup>+</sup> recipients (analogous to a normal CRU assay).

Statistical Analysis. The Student’s t test was used for the comparison of the mean of various hematological parameters from WT animals with that from p55<sup>-/-</sup> or p75<sup>-/-</sup> animals, unless otherwise stated.

**Results**

**Young Mice Lacking a p55 TNFR Show an Increase in Myeloid Progenitors in Their BM, but No Other Hematopoietic Differences.** Several assays were performed to assess the various lineages and subpopulations of the hematopoietic system (Table I). In young TNFR<sup>-/-</sup>-deficient mice (<3 mo), the WBC and RBC counts in the PB did not differ from those of WT mice, nor did the relative contributions to the several myeloid and lymphoid lineages (data not shown). The PB indices were mirrored by similar BM cellularity in these three strains of mice. Functional analysis of marrow cell suspensions revealed a significantly higher number of myeloid clonogenic cells in p55<sup>-/-</sup> mice compared with WT mice (P < 0.01), but no significant differences were observed in the number of erythroid and pre-B clonogenic cells or CRU.

Old p55<sup>-/-</sup> Mice Show Significant Differences in Their Hematopoietic System Compared with WT Mice. We hypothesized that an effect of perturbed TNFR signaling in HSCs may only be measurable with increased age. Therefore, we performed the same series of hematopoietic cell assays with BM cells from older mice (>6 mo). Neither the WT nor the p75<sup>-/-</sup> mice showed any significant change with aging, aside from the normalization of the WBC counts in p75<sup>-/-</sup> mice. In contrast, a profound disturbance of hematopoiesis in older p55<sup>-/-</sup> mice could be demonstrated (Table II). Early twice as many WBCs were found in the blood (P < 0.0005), and this was paralleled by the BM cell counts (P < 0.005). Moreover, FACS<sup>®</sup> analysis of the various mature lineages (Fig. 1 A) showed a tendency to increased cell numbers in all lineages except the B cell lineage. The same tendency was observed for clonogenic progenitors (Fig. 1 B). When all myeloid CFCS, i.e., BFU-E, CFU-G/M, and CFU-GEMM, were combined, the total number of colonies in p55<sup>-/-</sup> marrow was shown to be significantly higher than in WT or p75<sup>-/-</sup> marrow (P < 0.01): 128,000 ± 38,300 vs. 85,400 ± 25,000 and 78,300 ± 28,000, respectively. To assess the status of immature progenitors, we performed CFU-S day 12 assays and immunolabeled BM cells to identify the Sca-1<sup>+</sup>Lin<sup>-</sup>/c-Kit<sup>+</sup> subpopulation. Similar to the mature myeloid clonogenic progenitors, the number of CFU-S day 12 in p55<sup>-/-</sup> BM cells was higher compared with WT (not significant) and p75<sup>-/-</sup> (P < 0.03) BM cells: 2,700 ± 500 vs. 2,100 ± 260 and 1,700 ± 450, respectively (Fig. 1 B). Fig. 2 depicts a representative FACS<sup>®</sup> profile of BM cells showing the parameters used to calculate the absolute number of Sca-1<sup>+</sup>Lin<sup>-</sup>/c-Kit<sup>+</sup> cells per femur. There is a considerably larger, although not statistically significant subpopulation of

| Table I. The numbers of various hematopoietic subpopulations in the blood and marrow of young (<3 mo) p55<sup>-/-</sup> or p75<sup>-/-</sup> Mice. Do Nots differ from those of young WT Mice. |
|-----------------|------------------|------------------|
| PB WBCs (×10<sup>9</sup>/μl) | WT  | p55<sup>-/-</sup> | p75<sup>-/-</sup> |
| 6.5 (2.3) | 7.6 (2.1) | 3.7 (0.9)* |
| PB RBCs (×10<sup>11</sup>/μl) | 7.7 (1.3) | 8.4 (0.6) | 7.5 (0.8) |
| BM cellularity (×10<sup>3</sup>/femur) | 15.6 (3.8) | 16.8 (2.9) | 16.0 (4.8) |
| BM CFCS (per femur) | 6.8 (1.2) | 9.4 (1.3)* | 6.0 (6.8) |
| BFU-E (×10<sup>3</sup>) | 3.0 (2.1) | 2.8 (2.1) | 3.2 (1.8) |
| CFU-G/M (×10<sup>3</sup>) | 31.7 (33.1) | 9.4 (7.2) | 21.6 (16.2) |
| CRU per femur | 600 | 700 | ND |

The numbers indicating the blood and BM cell counts and CFCS represent the mean (± SD) of three separate experiments. The CRU assay was performed once.

*WT vs. p75<sup>-/-</sup>, not significant; p55<sup>-/-</sup> vs. p75<sup>-/-</sup>, P < 0.02.

†WT vs. p55<sup>-/-</sup>, P < 0.01.

---

| Table II. Cell counts of the blood and marrow from old WT and knock-out mice (>6 mo) reveal an increased cell output in p55<sup>-/-</sup> Mice. |
|-----------------|------------------|------------------|
| PB WBCs (×10<sup>9</sup>/μl) | WT  | p55<sup>-/-</sup> | p75<sup>-/-</sup> |
| 5.5 (1.1) | 9.4 (1.9)* | 5.5 (1.1) |
| PB RBCs (×10<sup>11</sup>/μl) | 8.4 (0.7) | 9.1 (0.5) | 7.8 (0.4) |
| BM cellularity (×10<sup>3</sup>/femur) | 15.8 (2.2) | 26.2 (5.9)* | 15.9 (2.6) |

Presented is the mean (± SD) from four separate experiments.

*WT vs. p55<sup>-/-</sup>, P < 0.0005.

†WT vs. p55<sup>-/-</sup>, P < 0.005.
Defect in Stem Cells of p55 TNFR–deficient Mice

Sca-1<sup>+</sup>Lin<sup>−/−</sup>c-Kit<sup>+</sup> cells in p55<sup>−/−</sup> BM compared with WT or p75<sup>−/−</sup> BM: 11,300 ± 6,400 vs. 4,800 ± 2,200 and 5,200 ± 2,400 cells, respectively. Since this subpopulation includes long-term repopulating HSCs (40), this phenotypic finding may indicate an increase in the number of HSCs in p55<sup>−/−</sup> BM. However, it has been clearly shown that phenotype does not always predict function (38, 41). Therefore, we performed competitive repopulating experiments under limiting dilution conditions to determine the number of CRU per femur (Table III). To our surprise, we found a significant decrease in the frequency of CRU among p55<sup>−/−</sup> BM cells compared with WT (P < 0.001). When corrected for BM cellularity, this translated into a near fourfold reduction of the absolute number of CRU in p55<sup>−/−</sup> mice (350 vs. 1,275 in WT mice). Taken together,

---

**Figure 1.** The numbers of mature and clonogenic progenitor cells, except pre-B cells, are increased in the BM from old p55<sup>−/−</sup> mice. (A) The mature cell compartment was assayed by immunolabeling the marrow cells with mAbs directed against mature lineage markers. (B) Clonogenic progenitors were measured in vitro (methylcellulose assay) and in vivo (CFU-S). For specific details, see Materials and Methods. The results represent the mean ± SD of data combined from three separate experiments.

**Table III.** Marrow cells from older p55<sup>−/−</sup> mice contain fewer CRU than BM cells from age-matched WT or p75<sup>−/−</sup> mice

| Donor cells | Experiment | Frequency (in total BM) | (95% confidence interval) | Average no. per femur |
|-------------|------------|------------------------|--------------------------|-----------------------|
| WT          | 1          | 1:12,500               | (5,700–27,500)           | 1,000                 |
|             | 2          | 1:12,200               | (5,600–26,400)           | 1,550                 |
| p55<sup>−/−</sup> | 1       | 1:55,100               | (22,900–132,300)         | 300                   |
|             | 2          | 1:70,700               | (32,750–152,500)         | 400                   |
| p75<sup>−/−</sup> | 1       | 1:20,700               | (7,250–59,000)           | 700                   |
|             | 2          | 1:14,800               | (7,000–31,400)           | 1,100                 |

Graded doses of unseparated BM cells from each mouse strain were injected into three groups of animals, five mice each. Presented are the results from two separate experiments, analyzed 16 wk after transplantation. For more details, see Materials and Methods.

* The combined data from p55<sup>−/−</sup> mice (i.e., CRU frequency of 1:64,200 [36,350–113,100]) compared with the combined data from WT mice (i.e., CRU frequency of 1:12,350 [7,100–21,500]) are significantly different (χ<sup>2</sup> test; P < 0.001).
These data show a tendency with aging in p55-deficient mice to increased sizes of most mature and immature hematopoietic (progenitor) cell populations, which could explain the overall increase in marrow cellularity found in these animals. At the same time, the number of HSCs that give rise to this variety of cell populations is reduced.

HSCs that lack the p55 receptor display impaired proliferative and self-renewal abilities. To further elucidate the extent of the stem cell defect in old p55−/− mice, we analyzed in detail the hematopoiesis of three sets of mice transplanted with low numbers of BM cells (Fig. 3, and Table IV). Groups 1 and 2 represent animals transplanted with 16,000 total BM cells (WT and p55−/−, respectively). A comparison of their donor repopulation kinetics as measured at various time points after transplant illustrates a dramatic decline in donor reconstitution over a 4-mo time period by p55−/− BM cells, whereas the donor reconstitution by WT cells showed a slight increase over the same time period tested (Fig. 3). 16 wk after transplantation, the level of donor cells in recipients of p55−/− BM cells (group 2) was significantly lower (P < 0.05) compared with that in recipients of WT BM cells (group 1) (1.1 ± 1.0 vs. 10.2 ± 12.2, respectively). The difference in repopulating ability between WT and p55−/− HSCs becomes even more apparent when individual mice are analyzed (Table IV). Between 4 and 16 wk after the transplantation, Ly5.2+ donor reconstitution did not increase in any of the recipients of p55−/− (Ly5.2−) BM cells. In contrast, more than half of all the animals that had received WT (Ly5.2+) BM cells showed an increase in Ly5.2+ cells, by as much as 38% in one of the recipients. Moreover, only 22% of the group 2 animals that were multilinesage reconstituted at week 4 remained so at week 16, compared with nearly 80% of the animals in group 1 (Table IV).

Thus, when equal numbers of BM cells are transplanted, the repopulating ability of p55−/− marrow cells is inferior to that of WT cells. However, when the CRU frequencies (Table III) were used to calculate the average number of CRU received by individual transplanted animals (i.e., the total number of cells transplanted divided by the frequency of CRU), it was calculated that group 1 had received on average 1 HSC, whereas group 2 had received on average 0.3 HSC. This could potentially explain, or at least contribute to, the observed differences. Therefore, we compared group 1 WT mice with a group of mice that received on

### Table IV

A analysis of the changes in the percentage of donor-derived nucleated blood cells (% Donor-repletion) at 4, 8, and 16 wk after the transplantation in three groups of animals. Group 1 (○) recipients received 16,000 unseparated WT BM cells. Groups 2 (□) and 3 (◆) received p55−/− cells: group 2 16,000 cells per mouse, and group 3 64,000 cells per mouse.

| Group (n) | Transplanted cells | Total cell no. (HSC) | Change in donor repopulation from week 4 to week 16 |
|-----------|--------------------|----------------------|-----------------------------------------------|
|           | Donor              |                      | Increase                                      |
|           |                    |                      | % ± SD (range) | % ± SD (range) | wk 4 (%) | wk 16 (%) |
| 1 (9)     | WT                 | 16,000 (1)           | 55 | 11.3 ± 15.4 (2.1–38.8) | 7.5 ± 5.5 (2.2–14.2) | 100 | 78 |
| 2 (9)     | p55−/−             | 16,000 (0.3)         | 0  | -             | 5.0 ± 4.2 (0.1–13.7) | 89  | 22  |
| 3 (10)    | p55−/−             | 64,000 (1)           | 10 | 0.4           | 14.0 ± 8.8 (3.5–34.3) | 100 | 70  |

*Indicated are the total number of Ly5.2+ BM cells transplanted per recipient. The average number of HSCs received per recipient is shown in parentheses.

**Mice that showed a decrease in donor reconstitution between weeks 4 and 16 were combined, and the mean of the decrease ± SD was calculated.**

The range of the values is shown in parentheses. The same was done with mice that showed an increase in donor repopulation. With % is indicated the fraction of animals within a group that showed a decrease/increase in the level of donor reconstitution or multilinesage reconstitution analyzed at the indicated time points after transplantation.
average 1 p55<sup>−/−</sup> HSC, equivalent to 64,000 total BM cells (group 3). As expected, approximately the same number of mice remained multilinage reconstituted after 16 wk (Table IV; 78% in group 1 and 70% in group 3). However, although 4 wk after the transplantation the level of donor reconstitution in group 3 (p55<sup>−/−</sup> transplant) recipients was significantly higher than in group 1 (WT transplant) recipients (P < 0.01), the percentage of donor p55<sup>−/−</sup> cells again, gradually decreased with each subsequent analysis (Fig. 3). 90% of all animals that received p55<sup>−/−</sup> marrow cells showed as much as a 34% decline in donor reconstitution (Table IV). Thus, not only does p55<sup>−/−</sup> marrow contain fewer HSCs, these data also indicate that the proliferative potential of p55<sup>−/−</sup> HSCs is less than that of WT HSCs.

To further stress the proliferative response of the Ly5.2<sup>+</sup> transplanted cells, BM cells of some of the primary recipients were transplanted into secondary recipients. The results of these experiments are shown in Table V. Eight primary recipients of WT marrow cells and three of p75<sup>−/−</sup> marrow cells were used in these experiments. Because we had not been able to demonstrate remarkable differences between WT and p75<sup>−/−</sup> hematopoiesis in older mice, we grouped these mice together to compare their secondary transplantation results to the results of the serially transplanted p55<sup>−/−</sup> marrow cells. Of 11 WT/p75<sup>−/−</sup> primary recipients, 4 animals (36%) contained Ly5.2<sup>+</sup> HSCs that generated multilineage progeny upon transplantation into secondary recipients. This proportion is in accordance with previous published data (42). Only 2 (18%) of the 11 primary recipients of p55<sup>−/−</sup> BM gave secondary reconstitution upon serial passage. As observed in the primary recipients of p55<sup>−/−</sup> cells, and in contrast to secondary recipients of WT donor cells, the kinetics of Ly-5.2<sup>+</sup> reconstitution in the secondary recipients showed a marked decline over time (data not shown).

Cell Cycle Analysis of p55<sup>−/−</sup>

Table V. Self-renewal in p55<sup>−/−</sup> HSCs

| Original Ly5.2<sup>+</sup> donor cells | N. o. of primary recipients used as donors | N. o. of Ly5.2<sup>+</sup> cells transplanted<sup>+</sup> | N. o. of primary recipients generating Ly5.2<sup>+</sup> progeny in secondary recipients 20 wk after transplant (average ± SD of Ly5.2<sup>+</sup> cells) |
|-------------------------------------|------------------------------------------|-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| WT/p75<sup>−/−</sup>                |                                          |                                               |                                                                                                                                        |
| 11                                 | 4.4 ± 2.0                                | 4 (8.8 ± 8.9)                                 |
| p55<sup>−/−</sup>                   | 5.4 ± 2.2                                | 2 (3.0 ± 1.6)                                 |

<sup>+</sup>BMM cells of primary recipients were harvested as usual and transplanted in three to five secondary recipients. The number of Ly5.2<sup>+</sup> (original) cells that was injected per secondary recipient was calculated by multiplying the total number of BM cells injected with the percentage of Ly5.2<sup>+</sup> cells determined in the blood by FACS<sup>®</sup> analysis. The difference between the number of cells transplanted from WT/p75<sup>−/−</sup> and p55<sup>−/−</sup> primary recipients is not significant.

<sup>†</sup>The level of Ly5.2<sup>+</sup> reconstitution in the p55<sup>−/−</sup> secondary recipients is significantly different compared with the WT/p75<sup>−/−</sup> group; P < 0.03.
Discussion

The p55 and p75 TNFRs are ubiquitously expressed on all hematopoietic cells, with the exception of erythroid and unstimulated T cells (2, 44). There is ample evidence from in vitro culture systems that, through one or both of these receptors, TNF-α can promote the expansion and differentiation of various hematopoietic subpopulations, as well as inhibit their proliferative response (10–13). However, the long-term effects of this cytokine in vivo as a possible regulator of steady state hematopoiesis, especially with regard to the stem cell compartment, are not well defined.

The present studies were undertaken to address this question by analyzing the hematopoietic system of mice in which TNF-α signaling is impaired. We and others (45) have shown that most hematopoietic subpopulations tested are present in young p55⁻/⁻ and p75⁻/⁻ mice at levels comparable to those of WT mice. In older mice, no significant differences in the assays tested between p75⁻/⁻ and WT mice could be demonstrated. However, when older p55⁻/⁻ mice were compared with WT mice they showed an interesting phenotype: their HSC compartment was significantly smaller than that of their WT counterparts (approximately fourfold), whereas the Sca-1⁻Lin⁻c-Kit⁺ CD34⁻ compartment had increased in size (approximately twofold). This was reflected in significant increases in total cellularity of the BM, total myeloid CFCs, and WBC and RBC counts in the PB. Thus, with aging of the mice, the lack of signaling through the p55 TNFR seems to affect the balance between generating new HSCs (self-renewal) and producing committed progenitors (differentiation). Interestingly, only the B cell lineage deviated from this pattern, in that the numbers of B220⁺ cells in the marrow (Fig. 1 A) and in the blood (data not shown) were similar to their WT counterparts, whereas the number of pre-B CFCs was significantly decreased in p55-deficient mice (Fig. 1 B). Previous studies have shown that the p55 TNFR is essential for the structural organization of lymphoid organs (46–49) and the number of B cells in the Peyer's patch (48). Our data also suggest that the generation of B cells in the marrow depends on p55 TNFR signaling. Whether this is mediated by TNF-α or lymphotixin α remains to be studied.

The proportion of total BM cells and Sca-1⁻/Lin⁻c-Kit⁺ CD34⁻ cells in S/G2/M phases of the cell cycle

| Total BM cells* | WT     | p55⁻/⁻ | p75⁻/⁻ |
|-----------------|--------|--------|--------|
| Sca-1⁻/Lin⁻/c-Kit⁺CD34⁻ | 2.3±0.6 | 9.4    | 9.2    |

The mice used for this analysis were all >6 mo.

*Shown are the mean values (± SD) from the combined data of five separate experiments.

10–20 mice were killed to obtain enough cells for a reliable PI DNA analysis. With WT marrow, this was done twice; with p55⁻/⁻ and p75⁻/⁻ marrow, once.
through the p55 TNFR increases the number of committed hematopoietic progenitors and their subsequent progeny at a cost to the stem cell pool. The scarcity of secondary recipients with multilineage p55−/− progeny confirms the lack of self-renewal or exhaustion of p55−/− HSCs. However, what is surprising and contrary to our expectations is the lower level of multilineage reconstitution per HSC from p55−/− donors compared with WT. The explanation for this reduction may be that hematopoietic regeneration in myeloablated recipients is different from both adult steady state hematopoiesis and fetal/neonatal hematopoiesis. Although little is known about the cytokines and other regulatory elements in the activation and/or recruitment of transplanted HSCs, there are some important differences compared with steady state hematopoiesis (61). One important difference is that transplanted HSCs must home to an appropriate microenvironment. It is possible that altered TNF-α signaling affects the homing properties of p55−/− cells. In this regard, it is of interest that TNF-α can affect the expression of CXC chemokine receptor 4 (62–64), a chemokine receptor critical for murine BM engraftment and regeneration as well as B cell development (65, 66). Moreover, in our experimental design, the transplanted HSCs and regeneration as well as B cell development (65, 66). Moreover, in our experimental design, the transplanted HSCs must home to an appropriate microenvironment. It is possible that altered TNF-α signaling affects the homing properties of p55−/− cells. In this regard, it is of interest that TNF-α can affect the expression of CXC chemokine receptor 4 (62–64), a chemokine receptor critical for murine BM engraftment and regeneration as well as B cell development (65, 66). Moreover, in our experimental design, the transplanted HSCs are influenced by stress-induced environmental changes associated with the myeloablation of the recipient. Stress can induce elevated levels of glucocorticoid hormones, which, in synergy with other cytokines, make BM cells more susceptible to IL-1 through upregulation of the IL-1 receptors, which favors myeloid differentiation (67, 68). A beneficial effect of IL-1 may be the suppression of apoptosis.

However, for this effect to be delivered, the combination of TNF-α may be essential (50). Therefore, it is possible that p55−/− HSCs acquire elevated levels of IL-1 receptors after transplantation but are more likely to differentiate than their WT counterparts when they do not receive the appropriate TNF signal. Thus, the loss of HSCs and all other hematopoietic cell types after transplantation of p55−/− marrow cells may not necessarily reflect steady state hematopoiesis, but rather the inability of these cells to adequately respond to extreme proliferative stimuli.

The need for intact TNF signaling in HSCs during hematopoietic regeneration of a myeloablated recipient may be more crucial for its survival than during steady state hematopoiesis. The G0/G1 arrest that TNF-α has been shown to induce in Sca-1+Lin−c-Kit+ cells may be imperative in restraining the proliferative response of HSCs to external stimuli and thereby preventing their extinction. In this respect, it is of interest that in TNF−/− mice it was shown that TNF is important for the generation of an inflammatory response, but its presence was far more essential in limiting the extent and duration of this response (69). This possible regulatory role in limiting the number of cell divisions in HSCs warrants further investigation, for example in retroviral gene therapy protocols with HSCs as target cells. Future studies of the role of TNF in steady state hematopoiesis should include the analysis of mice older than 20 mo and the generation of allophenic mice, which would allow the tracking of HSC progeny over time, without perturbing the hematopoietic system (70).

References

1. Carswell, E.A., L.J. Old, R.L. Kassel, S. Green, N. Fiore, and B. Williamson. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 72: 3666–3670.

2. Beyert, R., and W. Fiers. 1998. Tumor necrosis factor and lymphotoxin. In Cytokines. A. Mire-Sluis and R. Thorpe, editors. Academic Press, Inc., San Diego. 335–360.

3. Smith, C.A., T. Farrah, and R.G. Goodwin. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 76:959–962.

4. Tartaglia, L.A., D. Pennica, and D.V. Goeddel. 1993. Ligand passing: the 75-kDa a tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa a TNF receptor. J. Biol. Chem. 268:18542–18548.

5. Grell, M., E. Douni, H. Wajant, M. Lohden, M. Clauss, B. Maxeiner, S. Georgopoulou, W. Lesslauer, G. Kollias, K. Pfizenmaier, and P. Scheurich. 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa a tumor necrosis factor receptor. Cell. 83:793–802.

6. Ruben, J., H. Bluethmann, and J.J. Peschon. 1997. Antiviral
activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J. Exp. Med. 186:1591–1596.

7. Weiss, T., M. Grell, B. Hessabi, S. Bourteele, G. Muller, P. Scheurich, and H. Wajant. 1997. Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site. J. Immunol. 158:2398–2404.

8. Grell, M., F.M. Becke, H. Wajant, D.N. Mannel, and P. Scheurich. 1998. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur. J. Immunol. 28:257–263.

9. Zheng, L., G. Fisher, R.E. Miller, J. Peschon, D.H. Lynch, and M.J. Lenardo. 1995. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377:348–351.

10. Jacobsen, S.E., F.W. Russett, C.M. Dubois, and J.R. Keller. 1992. Tumor necrosis factor α directly and indirectly regulates hematopoietic progenitor cell proliferation: role of colony-stimulating factor receptor modulation. J. Exp. Med. 175:1759–1772.

11. Rogers, J.A., and J.W. Bernan. 1994. TNF-α inhibits the further development of committed progenitors while stimulating multipotent progenitors in mouse long-term bone marrow cultures. J. Immunol. 153:4694–4703.

12. Rusten, L.S., F.W. Jacobsen, W. Lesslauer, H. Loetscher, E.B. Rogers, and J.W. Berman. 1994. TNF-alpha inhibits the proliferation of primitive murine hematopoietic progenitor cells in vitro and primitive human hematopoietic progenitor cells involvement of p55 and p75 TNF receptors. Blood 83:3152–3159.

13. Snoeck, H.W., S. Weekx, A. Moulijn, H. Fardon, M. Lenou, G. Nys, P.C. Van Ranst, D.R. Van Bockstaele, and Z.N. Berneman. 1996. Tumor necrosis factor α is a potent synergistic factor for the proliferation of primitive hematopoietic progenitor cells and induces resistance to transforming growth factor β but not to interferon γ. J. Exp. Med. 183:705–710.

14. Shieh, J.H., R.H. Peterson, D.J. Warren, and M.A. Moeore. 1989. Modulation of colony-stimulating factor-1 receptors on macrophages by tumor necrosis factor. J. Immunol. 143: 2534–2539.

15. Elbaz, O., L.M. Budel, H. Hogerbrugge, I.P. Touw, R. Delwel, L.A. Mhamoud, and B. Lowenberg. 1991. Tumor necrosis factor downregulates granulocyte-colony-stimulating factor receptor expression on human acute myeloid leukemia cells and granulocytes. J. Clin. Invest. 87:838–841.

16. Jacobsen, F.W., C.M. Dubois, L.S. Russeen, O.P. Veby, and S.E. Jacobsen. 1995. Inhibition of stem cell factor-induced proliferation of primitive murine hematopoietic progenitor cells signaled through the 75-kilodalton tumor necrosis factor receptor. Regulation of c-kit and p53 expression. J. Immunol. 154:3732–3741.

17. Durig, J., E.A. de Wynter, C. Kaper, M.A. Cross, J. Chang, N.G. Testa, and C.M. Heyworth. 1997. Expression of macrophage inflammatory protein-1 receptors in human CD34(+) hematopoietic cells and their modulation by tumor necrosis factor-alpha and interferon-gamma. Blood. 92:3073–3081.

18. Unkler, R., J. Gasson, M. O’gawa, and H.P. Koehler. 1986. A recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature 323:79–82.

19. Sieff, C.A., C.M. Niemeyer, S.J. Mentzer, and D.V. Faller. 1988. Interleukin-1, tumor necrosis factor, and the production of colony-stimulating factors by cultured mesenchymal cells. Blood. 72:1316–1323.

20. Nawroth, P.P., I. Bank, D. Hantley, J. Casimeris, L. Chess, and D. Stern. 1986. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J. Exp. Med. 163:1363–1375.

21. Koefler, H.P., J. Gasson, J. Ranyard, L. Souza, M. Shepard, and R. Munker. 1987. A recombinant human TNF alpha stimulates proliferation of granulocyte colony-stimulating factor. Blood. 70:55–59.

22. Zucali, J.R., H.E. Broxmeyer, M.A. Gross, and C.A. Dinarello. 1988. A recombinant human tumor necrosis factors alpha and beta stimulate fibroblasts to produce hematopoietic growth factors in vitro. J. Immunol. 140:840–844.

23. Khoury, E., F.M. Lemoin, C. Ballou, J. Kobiari, C. Deloux, M. Guigon, and A. Najman. 1992. Tumor necrosis factor alpha in human long-term bone marrow cultures distinct effects on nonadherent and adherent progenitors. Exp. Hematol. 20:991–997.

24. Vandenberg Berge, W., S. Plaisance, E. Boone, K. De Bosscher, M.L. Schmitz, W. Fiers, and G. Hageman. 1998. P38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J. Biol. Chem. 273:3285–3292.

25. Pawliuk, R., C. Eaves, and R.K. Humphries. 1996. Evidence of both ontogeny and transplant dose-regulated expansion of hematopoietic stem cells in vivo. Blood. 88:2852–2858.

26. Ploemacher, R.E., P.L. van Soest, and A. Boudewijn. 1993. Autocrine transforming growth factor beta 1 blocks colony formation and progenitor cell generation by hematopoietic stem cells stimulated with steel factor. Stem Cells (Dayton). 11: 336–347.

27. Ohishi, K., N. Katayama, R. Itoh, N. Mahmud, H. Miwa, K. Kita, N. Minami, S. Shirakawa, S.D. Lyman, and H. Shiku. 1996. Accelerated cell-cycling of hematopoietic progenitors from quiescence by antisense transforming growth factor β1 or β2 oligonucleotides. J. Exp. Med. 174:925–929.

28. Zhang, Y., A. Harada, H. Bluethmann, J.B. Wang, S. Nakao, K. Koeffler, and R.K. Humphries. 1996. The growth response of Lin(−)Thy-1− hematopoietic progenitors to cytokines is determined by the balance between synergy of multiple stimulators and negative regulation of both ontogeny and transplant dose-regulated expansion of hematopoietic stem cells. Blood. 90:3073–3081.

29. Zucali, J.R., H.E. Broxmeyer, M.A. Gross, and C.A. Dinarello. 1988. A recombinant human tumor necrosis factors alpha and beta stimulate fibroblasts to produce hematopoietic growth factors in vitro. J. Immunol. 140:840–844.

30. Bradford, G.B., B. Williams, R. Rossi, and I. Bertoncello. 1996. Tumor necrosis factor alpha and beta stimulate fibroblasts to produce hematopoietic growth factors in vitro. Blood. 88:2852–2858.

31. Ebel, V.I., C.L. Miller, J.J. Spinelli, T.E. Thomas, C.J. Eaves, and P.M. Lansdorp. 1995. Nonlinear effects of radiation dose on donor-cell reconstitution by limited numbers of purified stem cells. Blood. 86:129–32.

32. Zucali, J.R., H.E. Broxmeyer, M.A. Gross, and C.A. Dinarello. 1988. A recombinant human tumor necrosis factors alpha and beta stimulate fibroblasts to produce hematopoietic growth factors in vitro. J. Immunol. 140:840–844.

33. Zucali, J.R., H.E. Broxmeyer, M.A. Gross, and C.A. Dinarello. 1988. A recombinant human tumor necrosis factors alpha and beta stimulate fibroblasts to produce hematopoietic growth factors in vitro. J. Immunol. 140:840–844.

34. Zucali, J.R., H.E. Broxmeyer, M.A. Gross, and C.A. Dinarello. 1988. A recombinant human tumor necrosis factors alpha and beta stimulate fibroblasts to produce hematopoietic growth factors in vitro. J. Immunol. 140:840–844.

35. Zucali, J.R., H.E. Broxmeyer, M.A. Gross, and C.A. Dinarello. 1988. A recombinant human tumor necrosis factors alpha and beta stimulate fibroblasts to produce hematopoietic growth factors in vitro. J. Immunol. 140:840–844.
35. Chervenick, P.A., D.R. Boggs, J.C. Marsh, G.E. Cartwright, and M.M. Wintrobe. 1968. Quantitative studies of blood and bone marrow neutrophils in normal mice. Am. J. Physiol. 215:353–360.

36. Till, J.E., and E.A. McCulloch. 1961. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Rad. Res. 6:141–222.

37. Szilvássy, S., K. Humphries, P.M. Lansdorp, A.C. Eaves, and C.J. Eaves. 1990. Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy. Proc. Natl. Acad. Sci. USA. 87:8736–8740.

38. Reibel, V.I., W. Dragowska, C.J. Eaves, R.K. Humphries, and P.M. Lansdorp. 1994. Amplification of Sca-1+Lin–WGA+ cells in serum-free cultures containing steel factor, interleukin-6, and erythropoietin with maintenance of cells with long-term in vivo reconstituting potential. Blood. 83:128–136.

39. Strijbosch, L.W., W.A. Buurman, R.J. Does, P.H. Zinken, and G. Groenewegen. 1987. Limiting dilution assays. Experimental design and statistical analysis. J. Immunol. Methods. 97:133–140.

40. Okada, S., H. Nakaochi, K. Nagayoshi, S. Nishikawa, Y. Miura, and T. Suda. 1992. In vivo and in vitro stem cell function of c-kit- and Sca-1-positive murine hematopoietic cells. Blood. 80:3044–3050.

41. Spangrude, G.J., D.M. Brooks, and D.B. Tumas. 1995. Long-term repopulation of fetal liver hematopoietic stem cells in mice exceeds that of their liver adult bone marrow counterparts. Blood. 87:3500–3507.

42. Reibel, V.I., C.L. Miller, C.J. Eaves, and P.M. Lansdorp. 1996. The repopulation potential of fetal liver hematopoietic stem cells in mice exceeds that of their liver adult bone marrow counterparts. Blood. 87:3500–3507.

43. Oowa, M., K. Hanada, H. Hanada, and H. Nakaochi. 1996. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science. 273:242–245.

44. Lewis, M., J.A. Tartaglia, A. Lee, G.L. Bennett, G.C. Rice, G.H.W. Wong, E.Y. Chen, and D.V. Goeddle. 1991. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl. Acad. Sci. USA. 88:2830–2834.

45. Pfeffer, K., T. Matsuzuma, T.M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P.S. Ohashi, M. Kronke, and T.W. Mak. 1993. Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 73:457–467.

46. Matsumoto, M., S. Miyauchi, M. N. Aham, F. Baranyay, J.J. Mossholt, and D.D. Chaplin. 1996. Role of lymphotixin and the type I TNF receptor in the formation of germinal centers. Science. 271:1289–1291.

47. Nourmam, B., A. Luz, K. Pfeffer, and B. Holzmann. 1996. Defective Peyer’s patch organogenesis in mice lacking the 55-kD receptor for tumor necrosis factor. J. Exp. Med. 184:259–264.

48. Papakakis, M., L. Alexopoulos, M. Grell, K. Pfizenmaier, H. Bluethmann, and G. Kollias. 1997. Peyer’s patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kD receptor. Proc. Natl. Acad. Sci. U.S.A. 94:6319–6323.

49. Tkachuk, M., S. Bolliger, B. Rutfeld, G. Pluschke, T.A. Banks, S. Heren, R.H. Gisler, and M.H. Kosco-Vilbois. 1998. Crucial role of tumor necrosis factor receptor 1 expression on nonhematopoietic cells for B cell localization within the splenic white pulp. J. Exp. Med. 187:469–477.

50. Jacobsen, F.W., O.P. Velby, T. Stokke, and S.E.W. Jacobsen. 1995. TNF-α bidirectionally modulates the viability of primitive murine hematopoietic progenitor cells in vitro. J. Immunol. 157:1193–1199.

51. Baker, S.J., and E.P. Reddy. 1996. Transducers of life and death: TNF receptor superfamily and associated proteins. 0. Nogone. 12:1–9.

52. Yuen, J. 1997. Transducing signals of life and death. Curr. Opin. Cell Biol. 9:247–251.

53. Ogawa, M. 1993. Differentiation and proliferation of hematopoietic stem cells. Blood. 81:2844–2853.

54. Lansdorp, P.M. 1997. Self-renewal of stem cells. Biol. Blood Marrow Transplant. 3:171–178.

55. Rosendaal, M., G.S. Hodgson, and T.R. Bradley. 1979. Organization of haematopoetic stem cells: the generation-age hypothesis. Cell Tissue Kinet. 12:17–29.

56. Tateda, K., T. Matsuzuma, S. Miyazaki, and K. Yamaguchi. 1992. Lipopolysaccharide-induced lethality and cytokine production in aged mice. Infect. Immun. 64:769–774.

57. Aggarwal, S., S. Gollapudi, and S. Gupta. 1999. Increased TNFα-induced apoptosis in lymphocytes from aged human: changes in TNF-α receptor expression and activation of caspases. J. Immunol. 162:2154–2161.

58. Morrison, S.J., A.M. Wandyck, K. Akashi, A. Globerson, and I.L. Weissman. 1996. The aging of hematopoietic stem cells. Nat. Med. 2:1011–1016.

59. Reibel, V.I., C.L. Miller, G.R. Thornbury, W.H. Dragowska, C.J. Eaves, and P.M. Lansdorp. 1996. A comparison of long-term repopulating hematopoietic stem cells in fetal liver and adult bone marrow from the mouse. Exp. Hematol. 24:638–648.

60. Miller, C.L., V.I. Reibel, C.D. Hlava, P.M. Lansdorp, and C.J. Eaves. 1997. Impaired steel factor responsiveness differentially affects the detection and long-term maintenance of fetal liver hematopoietic stem cells in vivo. Blood. 89:1214–1223.

61. Miller, C.L., V.I. Reibel, M.E. Lemieux, C.D. Hlava, P.M. Lansdorp, and C.J. Eaves. 1996. Studies of W mutant mice provide evidence for alternate mechanisms capable of activating hematopoietic stem cells. Exp. Hematol. 24:185–194.

62. Gupta, S.K., P.G. Lysko, K. Pillarsetti, E. O’Hlisite, and J.M. Stadel. 1998. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J. Biol. Chem. 273:4282–4287.

63. Feil, C., and H.G. Augustin. 1998. Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR4-fusin) under the control of autocrine activity and exogenous cytokines. Biochem. Biophys. Res. Commun. 247:38–45.

64. Sallusto, F., P. Schieler, P. Loetscher, C. Schenki, D. Lenig, C.R. Mackay, S. Qin, and A. Lanzavecchia. 1998. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 28:2760–2769.

65. Kawabata, K., M.E.T. Ujikawa, H. Kawamoto, K. Tachi-bana, H. Iizasa, Y. Katsura, T. Kishimoto, and T. Nagasawa. 1999. A cell-autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution. Proc. Natl. Acad. Sci. U.S.A. 96:5663–5667.
66. Zou, Y.R., A.H. Kottmann, M. Kuroda, I. Taniuchi, and D.R. Littman. 1998. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 393:595–599.
67. Besedovsky, H., A. del Rey, E. Sorkin, and C.A. Dinarello. 1986. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science. 233:652–654.
68. Dubois, C.M., R. Neta, J.R. Keller, S.E. Jacobsen, J.J. Oppenheim, and F. Ruscetti. 1993. Hematopoietic growth factors and glucocorticoids synergize to mimic the effects of IL-1 on granulocyte differentiation and IL-1 receptor induction on bone marrow cells in vivo. Exp. Hematol. 21:303–310.
69. Marino, M.W., A. Dunn, D. Grai, M. Inglese, Y. Noguchi, E. Richards, A. Jungbluth, H. Wada, M. Moore, B. Williamson, et al. 1997. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA. 94:8093–8098.
70. Van Zant, G., J.J. Chen, and K. Scott-Micus. 1991. Developmental potential of hematopoietic stem cells determined using retrovirally marked allophenic marrow. Blood. 77: 756–763.